Welcome to our dedicated page for Hologic SEC filings (Ticker: HOLX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Hologic, Inc. (Nasdaq: HOLX) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures filed with the U.S. Securities and Exchange Commission. As a Delaware corporation with common stock registered under Section 12(b) of the Exchange Act and listed on The Nasdaq Stock Market LLC, Hologic submits periodic and current reports that offer detailed insight into its operations, financial performance and material corporate events.
Among the most closely watched documents for Hologic are its annual reports on Form 10-K and quarterly reports on Form 10-Q, which describe the company’s diagnostics, breast health, GYN surgical and skeletal health businesses, outline risk factors and discuss segment performance. Current reports on Form 8-K provide timely updates on specific events, such as quarterly earnings releases, changes to executive compensation arrangements and material transactions.
Recent 8-K filings have included the announcement of financial results for the fourth quarter of fiscal 2025, along with reconciliations of non-GAAP measures such as adjusted EBITDA and non-GAAP EPS, and the disclosure of a revised form of restricted stock unit award agreement approved by the Compensation Committee. Another 8-K details the Agreement and Plan of Merger under which a merger subsidiary affiliated with funds managed by Blackstone and TPG will merge with and into Hologic, with Hologic surviving as a wholly owned subsidiary of a parent entity. That filing also notes that, if the merger is consummated, Hologic’s common stock will be delisted from Nasdaq and deregistered under the Exchange Act.
On this page, users can review Hologic’s 8-K filings related to transaction announcements, executive employment agreement amendments and results of operations, alongside its periodic reports when available. These filings help investors understand how Hologic’s diagnostics, breast health, GYN surgical and skeletal health segments contribute to overall results, how non-GAAP metrics are defined, and how material agreements—such as the proposed merger with Blackstone- and TPG-affiliated entities—may affect the company’s capital structure and listing status.
Stock Titan enhances access to these documents by pairing them with AI-powered summaries that explain key points in plain language. This can be especially helpful for lengthy filings like 10-K and 10-Q reports, as well as complex transaction-related 8-Ks. Users interested in HOLX can use this page to monitor new filings as they appear on EDGAR, review historical disclosures and track how Hologic’s regulatory reporting reflects developments in its medical technology and women’s health businesses.
Hologic Inc. General Counsel Anne M. Liddy reported a small share disposition related to taxes, not an open-market sale. On the transaction date, 185 shares of common stock were withheld at $75.36 per share to cover tax obligations from vested restricted stock units. After this tax-withholding disposition, she directly owned 28,052 Hologic shares.
Hologic Inc. director Amy McBride reported an acquisition of 3,190 shares of common stock in the form of restricted stock units. These units vest on the date of the 2027 Annual Meeting of Stockholders and will be settled one-for-one in common shares, bringing her direct holdings to 25,784 shares.
Hologic director Stacey D. Stewart reported an equity grant of 3,190 restricted stock units on February 26, 2026. The award has no cash exercise price and will vest on the date of the 2027 Annual Meeting of Stockholders, then be settled in shares of common stock.
After this grant, Stewart directly holds 8,358 shares and units in total, including 3,436 restricted stock units whose settlement has been deferred under Hologic’s Deferred Equity Plan.
Stamoulis Christiana reported acquisition or exercise transactions in this Form 4 filing.
Hologic Inc. director Christiana Stamoulis reported an equity award of 3,190 restricted stock units (RSUs) of common stock. The RSUs were granted at no cash purchase price and will vest on the date of Hologic’s 2027 Annual Meeting of Stockholders.
Each restricted stock unit will be settled in one share of Hologic common stock on a one-for-one basis. After this award, Stamoulis directly holds 50,526 shares of Hologic common stock, reflecting her updated ownership position as reported in the filing.
Hologic Inc. director Nanaz Mohtashami received an equity award in the form of restricted stock units. On the reported date, she acquired 3,190 RSUs at no cash cost, classified as a grant or award acquisition. Following this grant, she now holds 7,371 shares of common stock in direct ownership.
The footnotes explain that these RSUs will vest on the date of Hologic’s 2027 Annual Meeting of Stockholders and will be settled in shares of common stock on a one-for-one basis, linking director compensation directly to future stock performance.
McMillan Wayde D. reported acquisition or exercise transactions in this Form 4 filing.
Hologic, Inc. director Wayde D. McMillan reported receiving an equity award of 3,190 restricted stock units of common stock. The award was granted at no cash cost per share and will vest on the date of Hologic’s 2027 Annual Meeting of Stockholders.
Each restricted stock unit will be settled in one share of Hologic common stock upon vesting. Following this grant, McMillan’s directly held common stock position increased to 4,932 shares, reflecting his equity-based alignment with shareholders.
Madaus Martin D reported acquisition or exercise transactions in this Form 4 filing.
Hologic director Martin D. Madaus reported an equity award of 3,190 restricted stock units of common stock on February 26, 2026. These units vest on the date of the 2027 Annual Meeting of Stockholders and are settled one-for-one in Hologic common shares.
After this grant, Madaus directly holds 5,396 common shares. A separate line shows indirect ownership of 5,445 common shares through a revocable trust, reflecting his holdings in that entity.
Hologic director Ludwig Hantson received an equity award in the form of restricted stock units. On the reported date, he was granted 3,190 RSUs tied to Hologic common stock at no cash cost, classified as a grant or award acquisition. These RSUs are scheduled to vest on the date of the 2027 Annual Meeting of Stockholders and will be settled one-for-one in shares of common stock. After this award, Hantson’s directly held stake is 16,146 shares, which includes 3,695 RSUs whose settlement has been deferred under Hologic’s Deferred Equity Plan.
Hologic Inc. director Charles J. Dockendorff acquired 3,190 restricted stock units of common stock as a grant. The award was recorded at a price of $0.0000 per share, reflecting a stock-based compensation grant rather than a market purchase.
These restricted stock units vest on the date of Hologic’s 2027 Annual Meeting of Stockholders and are settled in shares of common stock on a one-for-one basis. After this grant, Dockendorff directly holds 6,626 shares of common stock, and indirectly holds 15,370 shares through a revocable trust.
T. Rowe Price Investment Management, Inc. filed an amended Schedule 13G reporting its beneficial ownership of Hologic, Inc. common stock as of December 31, 2025.
The firm reports beneficial ownership of 5,932,301 shares of Hologic common stock, representing 2.7% of the class. It has sole power to vote 5,914,773 shares and sole power to dispose of 5,932,301 shares, with no shared voting or dispositive power.
The filer states that the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of Hologic. It also expressly denies that this filing should be construed as an admission of beneficial ownership of the reported securities.